Kirk Hinkley, MD
General Practice · Hallstead, PANPI 1366484198
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,510 of the $58,984 with a category attached, or 72.1%. Vapotherm Inc accounts for 93.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $53,908 and has fallen 97.7% since, to $1,260 in 2025. Among general practice clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $185.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vapotherm Inc$55K
- Novo Nordisk$1K
- Lilly USA, LLC$547
- Merz North America, Inc.$506
- AstraZeneca$389
- GSK$355
- plus $1K from 17 others
What the payments were for
- Consulting fees$42,51072%
- Travel & lodging$10,08317%
- Food & beverage$6,38111%
- Gifts$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vapotherm Inc | 117 | $54,925 |
| Novo Nordisk | 73 | $1,142 |
| Lilly USA, LLC | 36 | $547 |
| Merz North America, Inc. | 6 | $506 |
| AstraZeneca | 18 | $389 |
| GSK | 15 | $355 |
| Boehringer Ingelheim | 11 | $301 |
| Verona Pharma, Inc. | 8 | $144 |
| Amgen | 6 | $104 |
| Exact Sciences | 5 | $104 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Indivior Inc. | 3 | $58 |
| Organogenesis Inc. | 2 | $56 |
| AbbVie | 2 | $51 |
| Abbott | 1 | $40 |
| Braeburn Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $29 |
| Si-bone, Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Gilead | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Precision Flow$51,815
- VAPOTHERM$1,012
- XEOMIN$429
- ASCLERA$429
How this compares
$58,984 in reported general payments places this provider in the 95th percentile of 3,208 general practice providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $139,816 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $132,094 |
| FarxigaDapagliflozin Propanediol | 87 | $111,466 |
| JardianceEmpagliflozin | 80 | $111,421 |
| TrulicityDulaglutide | 67 | $107,485 |
| OzempicSemaglutide | 65 | $92,921 |
| RinvoqUpadacitinib | 11 | $63,766 |
| MounjaroTirzepatide | 37 | $50,192 |
| AtivanLorazepam | 12 | $44,511 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $40,623 |
| JanuviaSitagliptin Phosphate | 16 | $26,181 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $20,023 |
| EntrestoSacubitril/Valsartan | 12 | $19,829 |
| TradjentaLinagliptin | 17 | $19,417 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $10,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $355 | $182,950144 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $547 | $157,677104 claims |
| PfizerEliquis | $15 | $139,816121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $389 | $131,489104 claims |
| Boehringer IngelheimJardiance, Tradjenta | $301 | $130,83897 claims |
| Novo NordiskOzempic | $1,142 | $92,92165 claims |
| AbbVieRinvoq, Synthroid | $51 | $65,86338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,208 general practice providers in Pennsylvania.
Other general practice in Hallstead
- Corey AnolikPhiladelphia$2.1M
- Richard NagelbergPlymouth Meeting$1.4M
- Alan AtlasPhiladelphia$486K
- Susan McMahonPittsburgh$364K
- Carl MedgausMonroeville$192K
- Yooson KimMorgantown$166K
- Michael WollockArdmore$113K
- Marc ManosPhiladelphia$85K
- Michele ColumboBryn Mawr$79K
- Robert MarusYardley$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.